Search

Your search for "cnsp" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit

June 5, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled “The Future and Promise of TPI 287,” will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer 

May 16, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor 

May 14, 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on brain and central nervous system cancers, has priced a “reasonable best efforts” public offering with a single healthcare-focused institutional investor, raising approximately $5 million in gross proceeds. The offering includes 3,952,570 shares of common stock at $1.265 per share and accompanying Series F warrants to purchase […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications

May 13, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position

April 1, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial 

March 25, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary endpoint of statistically significant improvement in overall survival compared to standard-of-care Lomustine, Berubicin showed comparable results across key clinical outcomes, including in patients with poor tumor […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress

February 26, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company focused on treatments for brain and central nervous system cancers, provided an update on its cash position and efforts to maintain its Nasdaq listing. The company reported a strengthened financial position, with $14 million in cash as of Feb. 26, 2025, expected to fund operations into the first […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

February 21, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management will also be available for one-on-one meetings with registered investors, and a video webcast of the presentation will be accessible […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

February 20, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry peers to follow the company in 2025. The presentation focused on CNS Pharmaceuticals’ advancements in developing treatments for primary and metastatic brain and central nervous system […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-50 Reverse Stock Split

February 19, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) announced a 1-for-50 reverse stock split of its common stock, set to take effect on Feb. 21, 2025. The company’s shares will continue trading on Nasdaq under the symbol “CNSP” but with a new CUSIP number: 18978H409. The reverse split aims to increase the per-share trading price and ensure compliance with […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit

February 18, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will present on Feb. 20 at 10:45 a.m. ET, discussing novel formulations of anthracyclines and taxanes designed to cross the blood-brain barrier. The company’s lead candidate, Berubicin, has […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference

February 10, 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the BIO CEO & Investor Conference in New York on Feb. 10-11, 2025. CEO John Climaco is scheduled to present on Feb. 10 at 1:15 p.m. ET in the Royale Room. Management will also […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11

December 5, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30 a.m. to 1 p.m. ET. The event will feature presentations by the company’s leadership team, including CEO John Climaco, Chief Medical Officer Dr. Sandra Silberman, and […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment

November 25, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent glioblastoma multiforme (“GBM”). Presented at the 29th Annual Meeting of the Society for Neuro-Oncology, the data show balanced patient demographics and safety profiles between the study arms, with Berubicin showing […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting

November 18, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) announced that its abstract on the pivotal trial of Berubicin, a novel treatment for glioblastoma multiforme (“GBM”), has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology. The presentation, led by Chief Medical Officer Dr. Sandra Silberman, will provide updates on the randomized, controlled CNS-201 […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position

November 15, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent glioblastoma multiforme (“GBM”). Enrollment of 252 patients was completed, with primary analysis data expected in the first half of 2025. Berubicin, which crosses the blood-brain barrier, has received Fast […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin’s Potential in Glioblastoma Treatment During KOL Connect Event

November 4, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, a renowned neuro-oncologist and National Coordinating Investigator for CNS’s study on Berubicin. During the event, Professor Weller discussed the urgent need for effective treatments in glioblastoma […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension for Compliance

November 1, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the Nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This extension allows CNS additional time to regain compliance and maintain its listing status. To view the full press release, visit […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering

October 24, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities purchase agreements with institutional investors to raise approximately $3 million. The funding will come from the sale of 17,647,060 shares of common stock, priced at $0.17 per […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment

October 10, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company announced Thursday morning that it participated in a Virtual Investor KOL Connect segment. Members of the company’s management team and Dr. Samuel Goldlust, who previously served […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Fireside Chat at 2024 Healthcare Virtual Summit

October 8, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming 2024 Healthcare Virtual Summit. The summit, which is presented by Maxim Group LLC, is scheduled for Oct. 16, 2024. According to the announcement, […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

September 23, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 4, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is slated for Sept. 9–11, 2024, in New York. According to the announcement, CEO […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode

September 3, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in the most recent episode of IBN’s BioMedWire Podcast. During the episode, CNS Pharmaceuticals CEO John Climaco talks with podcast host Carmel Fisher to explain what sets […]

Press Releases

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

September 3, 2024

LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast features fast-paced interviews […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

August 27, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that CEO John Climaco will present and discuss recent corporate events at the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investor Webinar. The […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment

August 22, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be spotlighted in this month’s Virtual Investor CEO Connect. According to the announcement CNS Pharmaceuticals CEO John Climaco will participate in a live moderated webcast to begin at […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results

August 15, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the second quarter ended June 30, 2024 (“Q2 2024”). The company also discussed the clinical development progress of Berubicin, its lead program, and […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Inks Exclusive License in ‘Transformational’ Step to Treating GBM

July 30, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into an exclusive license agreement with Cortice Biosciences Inc. Through the agreement, CNS Pharmaceuticals has acquired a license as well as the intellectual property rights to a […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CMO to Present Poster at Upcoming SNO/ASCO CNS Cancer Conference

July 25, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held Aug. 8–10 in Denver. According to the announcement, CNS Pharmaceuticals has an abstract, […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Exec to Present at Upcoming Virtual Investor Closing Bell Series

July 16, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in tomorrow’s Virtual Investor Closing Bell Series. According to the announcement, CNS Pharmaceuticals CEO John Climaco will be presenting via a live video webcast at 4 […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Securities Purchase Agreements Worth Estimated $1.98M

July 5, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements, which are for the purchase and sale of 1,425,000 shares of common stock, are comprised of […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of Registered Direct, Concurrent Private Placement

June 26, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced its entry into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 568,000 shares of common stock in a […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters in Purchase Agreements, Announces Pricing

June 17, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements are for the purchase and sale of 366,000 shares of common stock, or common stock equivalents […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company Showcase

May 20, 2024

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners. Climaco’s […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report

May 16, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024

April 23, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced that its Chief Executive Officer John Climaco will present at the LSX World Congress 2024. Climaco is slated to present at 4:15 PM (GMT+1) on Monday, April […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event

April 22, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured on the Virtual Investor Lunch Break: The CNSP Opportunity event. During the live video webcast, which is scheduled to begin at 12 p.m. EST, CEO John Climaco will […]

InvestorNewsBreaks

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

April 15, 2024

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. “A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).